Summary:
A clinical research study being conducted to see if an investigational drug combined with insulin glargine can improve blood sugar levels in people with type 2 diabetes more effectively than other commercially available anti-diabetes medication. The experimental medication, a lixisenatide/insulin glargine combination, will be compared to an anti-diabetes class of medication called GLP-1 agonist for example Victoza, Byetta, Bydureon, Tanzeum, Eperzan, or Trulicity with an oral anti-diabetic medication metformin and with or without Actos.
Qualified Participants Must:
• Be at least 18 years of age
•
Have been diagnosed with type 2 diabetes for at least 1 year
•
Have been treating your diabetes with Metformin and another anti-diabetes medication called GLP-1 for example Victoza, Byetta, Bydureon, Tanzeum, Eperzan, or Trulicity for at least 4-6 months and your diabetes is not adequately controlled with this treatment
Qualified Participants May Receive:
Up to $450.00 in compensation and all study-related care and medication is provided at no cost